HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary.

Abstract
Persons with inflammatory bowel disease (IBD) make up more than 0.75% of the Canadian population in 2021. Early in the COVID-19 pandemic, individuals with IBD, particularly those on immunosuppressive therapies, were concerned that their health status may place them at higher risk of contracting COVID-19 or experiencing more severe disease course if infected with SARS-CoV-2. In response, Crohn's and Colitis Canada developed the COVID-19 and IBD Taskforce in March 2020 to rapidly synthesize the evolving knowledge of COVID-19 as relevant to Canadians with IBD. The Taskforce communicated expert information directly to the Canadian IBD community through online tools and a webinar series. In order to understand the full impact of COVID-19 on the IBD community, Crohn's and Colitis Canada commissioned a policy report that was informed through a systematic literature review and synthesized across working groups along the following domains: Epidemiology, Children and Expectant Mothers with IBD, Seniors with IBD, Mental Health, Risk Factors and Medications, Vaccines, and Healthcare Delivery during the Pandemic and the Future Model of IBD Care. This report from Canadian physicians, researchers, and IBD community representatives highlights the physical, mental, and health systems impact of COVID-19 on the entire spectrum of the IBD community, including children, adolescents, adults, seniors, and pregnant people with IBD. This executive summary provides an overview of the crucial information from each of the chapters of the policy report, supplemented with additional information made available through Crohn's and Colitis Canada's webinar-based knowledge translation platform.
AuthorsM Ellen Kuenzig, Joseph W Windsor, Lisa Barrett, Charles N Bernstein, Alain Bitton, Matthew W Carroll, Usha Chauhan, Stephanie Coward, Sharyle Fowler, Jean-Eric Ghia, Rose Geist, Deanna L Gibson, Lesley A Graff, Anne M Griffiths, James Guoxian Huang, Jennifer L Jones, Reena Khanna, Peter L Lakatos, Kate Lee, David R Mack, John K Marshall, Mariam S Mukhtar, Sanjay K Murthy, Geoffrey C Nguyen, Remo Panaccione, Cynthia H Seow, Harminder Singh, Parul Tandon, Laura E Targownik, Sandra Zelinsky, Eric I Benchimol, Gilaad G Kaplan
JournalJournal of the Canadian Association of Gastroenterology (J Can Assoc Gastroenterol) Vol. 4 Issue Suppl 2 Pg. S1-S9 (Dec 2021) ISSN: 2515-2092 [Electronic] England
PMID34755033 (Publication Type: Journal Article)
Copyright© The Author(s) 2021. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: